Gallois C, et al. Background: The combination of encorafenib with cetuximab has become the standard of care in patients with BRAF V600E mutated metastatic colorectal cancer (mCRC), after a prior systemic therapy. This retrospective study aims to describe the efficacy and safety of encorafenib with cetuximab combination in the real-world setting. Methods: All consecutive patients...
Author: s.mengoni@pensiero.it
First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group
Punt CJA, Bond MJG, Bolhuis K, et al. Background: CAIRO5 aimed to find the optimal systemic induction regimen to convert initially unresectable CRLM to local treatment.Previously, we showed that for patients with right-sided and/or RAS/BRAFV600E mutated tumours PFS was significantly longer and complete local treatment (R0/R1 resection and/or ablation) higher with FOLFOXIRI vs FOLFOX/FOLFIRI, both...
Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated mCRC: CodeBreak 300 phase III study
Pietrantonio F, Salvatore L, Esaki T, et al. Background: We report the first Phase 3 primary results for sotorasib (soto), a KRASG12C-inhibitor, plus panitumumab (pani), an anti-EGFR antibody, vs standard of care (SOC) in patients (pts) with chemorefractory KRAS G12C-mutated mCRC. Methods: In the CodeBreaK 300 (NCT05198934) global, open label study, 160 pts with chemorefractory...
Circulating tumor DNA dynamics and clinical outcome in mCRCpatients undergoing front-line chemotherapy
Ghidini M, Hahne JC , Senti C, et al. Background: The potential of monitoring circulating tumor DNA (ctDNA) dynamics to guide clinical decisions in metastatic colorectal cancer patients treated with I and II line systemic anti-cancer therapy (SACT) has not been widely tested. Methods: 862 serial plasmas were collected 4-weekly from baseline (BL) until disease...
The effect of BRAFV600E mutation on survival and treatment efficacy in vulnerable older patients with mCRC – A post-hoc exploratory analysis of the randomized NORDIC9-study
Liposits G Winther SB, Ryg J, et al. Colorectal cancer is common, with the highest incidence and mortality rate observed in adults ≥70 years [1]. Through the past decades,survival has substantially improved in young and fit patients with metastatic colorectal cancer (mCRC) eligible for intensive treatment including chemotherapy combinations (doublet/triplet) and monoclonal antibodies, e.g., vascular...
Sequential treatment with regorafeniband trifluridine/tipiracil +/- bevacizumab in refractory mCRC in community clinical practice in the USA
Bekaii-Saab T, Ahn D, Yuan C, et al. Background: REG and TAS are approved for the treatment of refractory mCRC. However, data on their sequential use in any setting is limited. The aim of this study was to describe the characteristics and clinical outcomes of patients (pts) with mCRC treated sequentially in community clinical practice...
SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC
Elena Elez E, Kopetz S, Tabernero J, et al. Patients with both BRAF V600E mutations and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) have poor prognosis. Currently, there are no specifically targeted first-line treatment options indicated for patients with mCRC whose tumors harbor both molecular aberrations. Pembrolizumab is a checkpoint inhibitor approved for the treatment...
Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer
Rasola C, Laurent-Puig P, André T, et al. Background: It is intuitively thought that early relapse is associated with poor survival after recurrence (SAR) in resected colon cancer (CC) patients, but this has never been formally studied. Methods: We pooled data from stage III patients treated with oxaliplatin-based adjuvant therapy in two phase III trials,...
mCRC, da ESMO 2023 strategie a bersaglio molecolare e conferme di real-world
Una strategia a bersaglio molecolare contro la proteina KRAS e conferme di real-world per la combinazione encorafenib-cetuximab nel setting con mutazione di BRAF. Il commento di Chiara Cremolini.
Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided mCRC: the DEEPER trial
Sunakawa Y, Shiozawa M, Watanabe T, et al. Background: The DEEPER trial, which evaluated m-FOLFOXIRI (irinotecan 150 mg/m2, oxaliplatin 85 mg/m2, 5-FU 2400 mg/m2) plus cetuximab (cet) vs. bevacizumab (bev) as initial treatment in terms of depth of response (DpR) as the primary endpoint in RAS wild-type mCRC, has demonstrated a significantly better DpR of...